Liraglutide or Exenatide Added to Oral Antidiabetics Compared for Glycemic Control in Type 2 Diabetes

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by impaired insulin secretion and action, leading to chronic hyperglycemia. Despite foundational treatments like metformin and sulfonylureas, many patients struggle to achieve optimal glycemic control over time, necessitating additional therapies. Glucagon-like peptide-1 receptor (GLP-1R) agonists represent a class of injectables that enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety, offering a multifaceted approach to T2D management. This trial aimed to evaluate the comparative efficacy of two prominent GLP-1R agonists when added to standard oral antidiabetic regimens.

This Phase 2/3 clinical trial enrolled subjects with Type 2 Diabetes in Europe and the USA who were already on stable treatment with either metformin, a sulfonylurea, or both. Participants were randomized to receive either liraglutide or exenatide in addition to their ongoing oral antidiabetic drugs (OADs). The primary evaluation period was 26 weeks, comparing the effect on glycemic control. Following this, a 52-week open-label extension phase (14 + 38 weeks) was conducted, where all subjects received liraglutide plus their OADs, regardless of their initial randomization arm. The specific doses and routes of administration for liraglutide and exenatide are not detailed in the abstract.

The provided abstract outlines the study design and objectives but does not present specific results or statistical findings regarding the comparative effects of liraglutide versus exenatide on glycemic control. No percentages, p-values, or fold-changes are available to report. The abstract indicates the trial's completion, suggesting data was collected, but the outcomes are not summarized here. Therefore, no concrete findings can be extracted from this record.